
    
      Based on Ki67 levels after two weeks of initial letrozole treatment in postmenopausal
      patients with hormone receptor positive, HER2 negative, stage II/III breast cancer, patients
      are either advised to continue letrozole treatment (if Ki67 <1%) or will be randomized
      between standard chemotherapy (AC-T) or ribociclib in combination with letrozole (if Ki67
      â‰¥1%).
    
  